Cohance Lifesciences Ltd files a revised Q2/H1 FY27 investor presentation, reporting Q2 revenue of ₹4,767 mn and a 7.4% reported EBITDA margin.
- Revenue fell 14.2% YoY and rose 12.9% QoQ; adjusted EBITDA margin was 9.6% versus 23.2% in Q2FY26.
- Reported net profit was ₹152 mn; adjusted net profit was ₹75 mn, versus ₹742 mn and ₹712 mn, respectively, a year earlier.
- Adjusted EBITDA includes ₹68 mn of one-time ESOP, merger and acquisition costs; management expects H2FY27 to be stronger than H1, supported by Small Molecule deliveries, API+ resilience and Sapala growth.
- The revised presentation corrects and aligns the version filed on 6 November.
